Prasad Kulkarni on dengue monoclonal antibodies

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

Read the full article:
https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

The Lancet Infectious Diseases in conversation with...  is part of the Lancet Group podcast offering. 

Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and senior editors Syeda Saleha Hassan and Phoebe Hall

Podcast editing: Matteo Simonetti

Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

Find the best science for better lives at lancet.com

Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv